Expert Interview
Examining the potential of VYVGART (efgartigimod alfa-fcab), the recently approved agent from Argenx, in treating Myasthenia Gravis
Ticker(s): ARGXInstitution: Wayne State University
- Professor of Neurology at Wayne State & Editor of the Journal of the Neurological Sciences, the journal of the World Federation of Neurology.
- Treats patients with neuro-immunologic diseases including MS, MG, CIDP, and myositis; currently personally follows 70 patients with MG, at least 10-15 are refractory as defined in the Phase 2 and Phase 3 study of eculizumab.
- Has been involved in many multicenter trials that have led to approval of several treatments for MS, MG and GBS.
How many patients with Myasthenia Gravis do you manage?
Added By: c_adminHave you prescribed VYVGART? # of patients
Added By: c_adminAre you concerned at all about the potential class effects of FcRn antagonists potentially increasing LDL levels in patients?
Added By: pharmaadvisorWhat are your thoughts on the recent termination of FcRn class clinical trials for subcutaneous admin, including ALXN 1830 (Orilanolimab)? Does that create any concern over the utilization of VYVGART?
Added By: pharmaadvisorHow do you expect to see Vyvgart impact IVIG use in MG treatment? What proportion of your patients with MG would you switch to Vyvgart and away from IVIG? What factors are considered when making that switch?
Added By: jsharon3What is the potential of Vyvgart in CIDP and how do you anticipate a shift away from IVIG/SCIG in favor of anti FcRns for CIDP treatment?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
